DNMT3A and acute myeloid leukemia: An intense interest in demethylating therapies for AML and MDS has been fueled by the presence of hallmark focal DNA hypermethylation that distinguishes leukemic blasts from normal hematopoietic progenitors, and by the high frequency of somatic mutations in genes that regulate the methylation of genomic DNA, including IDH1/2, TET2, and DNMT3A [1,2,4,5], in myeloid malignancies.